Company to provide update on its lead drug candidate, GPX-001 for non-small cell lung cancer, and its preclinical diabetes gene therapy candidate that may have the potential to cure Type 1 and Type 2 diabetes
Genprex’s CEO participates in a live interview with the “Big Biz Show” for a second time, providing details on its lead drug candidate for NSCLC, its diabetes gene therapy and what lies ahead in the next 18 months in the midst of COVID-19.
Grant to fund ongoing preclinical research for important proof-of-principle non-human studies in preparation for human gene therapy clinical trials
Designed and Secured by Barsec